Julia W Erath1, Mate Vamos1, Alexander P Benz1, Stefan H Hohnloser2. 1. Department of Cardiology/Division of Clinical Electrophysiology, University Hospital Frankfurt, Goethe University, Frankfurt a. M., Germany. 2. Department of Cardiology/Division of Clinical Electrophysiology, University Hospital Frankfurt, Goethe University, Frankfurt a. M., Germany. hohnloser@em.uni-frankfurt.de.
Abstract
AIMS: The wearable cardioverter defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death. There is limited experience regarding the clinical development of patients with tachymyopathy. We aimed to evaluate the clinical development of tachymyopathy patients protected with a WCD in a single-center non-randomized patient cohort. METHODS AND RESULTS: We fitted 130 consecutive patients deemed to be at high risk for ventricular tachyarrhythmias with the WCD. Of these, 20 patients (15%) presenting with newly diagnosed heart failure in the setting of rapidly conducted atrial fibrillation/flutter were suspected to suffer from tachymyopathy. The control group consisted of the remaining 110 patients with other indications for WCD therapy. LVEF increased by more than 10% in 13/20 (65%) tachymyopathy patients compared to 40/110 (36%) patients in the control population (p = 0.01). Similarly, BNP levels decreased in 15/20 (75%) tachymyopathy patients compared to 41/110 (37%) in the control group (p = 0.05). ICD implantation rates were lower in the tachymyopathy group (3/20) compared to the control population (40/110; p = 0.04). On further follow-up (mean 12 ± 8 months), patients with suspected tachymyopathy had no sustained ventricular arrhythmias. Compared to 5/110 patients in the control group, no tachymyopathy patient died. CONCLUSION: Most of the patients with suspected tachymyopathy have a favorable clinical outcome. The WCD is useful for temporary protection while LV function recovers.
AIMS: The wearable cardioverter defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death. There is limited experience regarding the clinical development of patients with tachymyopathy. We aimed to evaluate the clinical development of tachymyopathy patients protected with a WCD in a single-center non-randomized patient cohort. METHODS AND RESULTS: We fitted 130 consecutive patients deemed to be at high risk for ventricular tachyarrhythmias with the WCD. Of these, 20 patients (15%) presenting with newly diagnosed heart failure in the setting of rapidly conducted atrial fibrillation/flutter were suspected to suffer from tachymyopathy. The control group consisted of the remaining 110 patients with other indications for WCD therapy. LVEF increased by more than 10% in 13/20 (65%) tachymyopathy patients compared to 40/110 (36%) patients in the control population (p = 0.01). Similarly, BNP levels decreased in 15/20 (75%) tachymyopathy patients compared to 41/110 (37%) in the control group (p = 0.05). ICD implantation rates were lower in the tachymyopathy group (3/20) compared to the control population (40/110; p = 0.04). On further follow-up (mean 12 ± 8 months), patients with suspected tachymyopathy had no sustained ventricular arrhythmias. Compared to 5/110 patients in the control group, no tachymyopathy patient died. CONCLUSION: Most of the patients with suspected tachymyopathy have a favorable clinical outcome. The WCD is useful for temporary protection while LV function recovers.
Authors: Tatjana S Potpara; Jelena M Marinkovic; Marija M Polovina; Goran R Stankovic; Petar M Seferovic; Miodrag C Ostojic; Gregory Y H Lip Journal: Int J Cardiol Date: 2011-05-12 Impact factor: 4.164
Authors: Ulrich Schotten; Maura Greiser; Dirk Benke; Kai Buerkel; Britta Ehrenteidt; Christoph Stellbrink; Jaime F Vazquez-Jimenez; Friedrich Schoendube; Peter Hanrath; Maurits Allessie Journal: Cardiovasc Res Date: 2002-01 Impact factor: 10.787
Authors: Arthur M Feldman; Helmut Klein; Patrick Tchou; Srinivas Murali; W Jackson Hall; Donna Mancini; John Boehmer; Mark Harvey; M Stephen Heilman; Steven J Szymkiewicz; Arthur J Moss Journal: Pacing Clin Electrophysiol Date: 2004-01 Impact factor: 1.976
Authors: Naiara Calvo; Felipe Bisbal; Esther Guiu; Pablo Ramos; Mercé Nadal; Jose María Tolosana; Elena Arbelo; Antonio Berruezo; Marta Sitges; Josep Brugada; Lluís Mont Journal: Int J Cardiol Date: 2013-07-23 Impact factor: 4.164
Authors: D L Packer; G H Bardy; S J Worley; M S Smith; F R Cobb; R E Coleman; J J Gallagher; L D German Journal: Am J Cardiol Date: 1986-03-01 Impact factor: 2.778
Authors: Béatrice Brembilla-Perrot; João Pedro Ferreira; Vladimir Manenti; Jean Marc Sellal; Arnaud Olivier; Thibaut Villemin; Daniel Beurrier; Christian De Chillou; Pierre Louis; Alice Brembilla; Yves Juillière; Nicolas Girerd Journal: Eur J Heart Fail Date: 2016-02-01 Impact factor: 15.534
Authors: David Duncker; Ralf Westenfeld; Torsten Konrad; Tobias Pfeffer; Carlos A Correia de Freitas; Roman Pfister; Dierk Thomas; Alexander Fürnkranz; René P Andrié; Andreas Napp; Jörn Schmitt; Laszlo Karolyi; Reza Wakili; Denise Hilfiker-Kleiner; Johann Bauersachs; Christian Veltmann Journal: Clin Res Cardiol Date: 2017-03-08 Impact factor: 5.460
Authors: Nadine K Wäßnig; Michael Günther; Silvio Quick; Christian Pfluecke; Fabian Rottstädt; Steven J Szymkiewicz; Steven Ringquist; Ruth H Strasser; Uwe Speiser Journal: Circulation Date: 2016-07-25 Impact factor: 29.690
Authors: Ahmad Masri; Ahmed M Altibi; Sebhat Erqou; Mohammad A Zmaili; Ala Saleh; Raed Al-Adham; Karam Ayoub; Moaaz Baghal; Laith Alkukhun; Amr F Barakat; Sandeep Jain; Samir Saba; Evan Adelstein Journal: JACC Clin Electrophysiol Date: 2019-01-30
Authors: Henrike Aenne Katrin Hillmann; Stephan Hohmann; Johanna Mueller-Leisse; Christos Zormpas; Jörg Eiringhaus; Johann Bauersachs; Christian Veltmann; David Duncker Journal: Sensors (Basel) Date: 2021-11-23 Impact factor: 3.576
Authors: Christian Veltmann; Stefan Winter; David Duncker; Carsten G Jungbauer; Nadine K Wäßnig; J Christoph Geller; Julia W Erath; Olaf Goeing; Christian Perings; Michael Ulbrich; Mattias Roser; Daniela Husser; Laura S Gansera; Korkut Soezener; Frank Michael Malur; Michael Block; Thomas Fetsch; Valentina Kutyifa; Helmut U Klein Journal: Clin Res Cardiol Date: 2020-05-06 Impact factor: 5.460